Amicus Therapeutics Inc

Amicus Therapeutics — Investor Presentation (November 2022)

32 slides from Amicus Therapeutics's investor presentation, Nov 16, 2022

  1. Slide 1: Corporate Overview November 2022

    Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements Thispresentationcontains"forward-lookingstatements"withinthemeaningofthePrivateSecuritiesLitigationReformActof1995relatingtopreclinicalandclinicaldevelopmentofourproductcandidates,thetimingandreportingofresultsfrompreclinicalstudiesandclinicaltrials,theprospectsandtiming

  3. Slide 3: A Rare Company

    3 A Rare Company Patient-dedicated, Rare Disease Biotechnology Company with Sustained Double-digit Revenue Growth, a Global Commercial Infrastructure, and Late-stage Development Capabilities AT-GAAa Two-component TherapyUnder GlobalRegulatory Reviews forPompe Disease GLOBAL COMMERCIAL ORGANIZATIONWo

  4. Slide 4: 2022 Strategic Priorities to Drive Value

    2022 Strategic Priorities to Drive Value 12345Double-digit Galafold growth (15-20%) with revenue of $350M to $365M at CER1Secure FDA approval and positive CHMP opinion for AT-GAA Initiate successful, rapid launch in U.S. for AT-GAAAdvance best-in-class, next-generation genetic medicines and capabili

  5. Slide 5: Amicus Pipeline

    5 INDICATIONDISCOVERYPRECLINICALPHASE 1/2PHASE 3REGULATORYCOMMERCIALFABRY FRANCHISEGalafold®(migalastat) Fabry Gene TherapyNext-Generation ChaperonePOMPE FRANCHISEAT-GAA (cipaglucosidase alfa + miglustat)Pompe Gene TherapyOTHERCLN3 Batten Disease Gene Therapy Next-Generation Research ProgramsAmicus

  6. Slide 6: Positioned for Significant Value Growth

    6 Positioned for Significant Value Growth Focused on Execution and Driving Sustainable Double-digit Revenue Growth on Path to ProfitabilityContinue to bring Galafold®to as many patients as possible, sustain double-digit revenue growthSuccessful launch of AT-GAA for people living with Pompe diseaseAd

  7. Slide 7: Galafold (migalastat): Continued Growth

    7 Galafold® (migalastat)Continued Growth… building a leadership position in the treatment of Fabry disease

  8. Slide 8: Global Fabry Market

    8 Global Fabry Market Fabry Disease is believed to be significantly underdiagnosed–Newborn screening studies suggest Fabry could be one of the more prevalent human genetic diseases (~1:1,000 to ~1:4,000 incidence) In 2021, Galafold was the fastest growing medicine for Fabry disease and the greatest

  9. Slide 9: Galafold Success

    9 GalafoldSuccess (as of September 30, 2022) Building on Galafold’s Success and LeveragingLeadership Position to Drive Continued Growth Galafold is indicated for adults with a confirmed diagnosis of Fabry Disease and an amenable variant. The most common adversereactions reported with Galafold (≥10%)

  10. Slide 10: Galafold Performance

    10 GalafoldPerformance YTD Reported Revenue Growth of +7.9% to $241.0M –Strong Operational Growth of +16.2% at CER Global demand remains strong: 3-month net new patients trend best in 2 years Call volume increasing from same period last year Global mix of switch (~55%) and previously untreated patie

  11. Slide 11: Galafold Growth Opportunity

    11 Penetration of the diagnosed untreated populationIncrease in newborn screening and diagnostic initiativesStrong IP rights, includingCOM protection through 2038Continued penetration into existing marketsExpansion into new geographiesBroadening of labels Galafold Growth Opportunity$1B Annual Sales

  12. Slide 12: Galafold Initiatives

    12 Galafold Initiatives Building the Body of the Evidence around Galafold Broadening Labels: Adolescents and Additional Variants Publications and Medical Presentations Ongoing and Planned Phase IV Studies Over 500 Patients Enrolled in a Global Registry Strengthening our IP Portfolio

  13. Slide 13: AT-GAA (cipaglucosidase alfa + miglustat)

    13 AT-GAA (cipaglucosidase alfa + miglustat)… potential to establish a new standard of care for people living with Pompe disease

  14. Slide 14: Pompe Disease Overview

    14 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Age of onset ranges from infancy to adulthood Symptoms include muscle weakness, respiratory failure, and cardiomyopathy Respiratory and cardiac failure are leading causes of morbidity and mortality Estimated inc

  15. Slide 15: AT-GAA: An Innovative Approach to Pompe Disease

    15 AT-GAA: An Innovative Approach to Pompe Disease Our Scientists Created a Uniquely Glycosylated and Highly Phosphorylated ERT (ATB200) that Significantly Enhances Targeting to Key Affected Muscles AT-GAA is a two-component therapy combining ATB200, an ERT, with AT2221, an orally administered enzym

  16. Slide 16: Phase 3 PROPEL Study Results: Endpoint Heat Map

    16 Phase 3 PROPEL Study ResultsPrimary, Key Secondary and Biomarker Endpoint Heat Map Endpoints Across Motor Function, Pulmonary Function, Muscle Strength, PROs, and Biomarkers Favored AT-GAA over alglucosidase alfa

  17. Slide 17: Phase 3 PROPEL Study Results: Overall Population

    17 Phase 3 PROPEL Study ResultsOverall Population (n=122*) Primary and First Key Secondary Endpoint Showed Greater Improvement with AT-GAA vs. alglucosidase alfa in the Overall Population of ERT-Naïve and ERT-Experienced Patients6MWD=6-minute walk distance;; FVC=forced vital capacity; SE=standard er

  18. Slide 18: PROPEL Topline Results: ERT Experienced Population

    18 Phase 3 PROPEL Topline Results:ERT Experienced Population (n=95) ERT Experienced Patients Treated with AT- GAA Demonstrated Improvements over Time in 6MWD and Stabilization over Time in FVC Versus alglucosidase alfa NOTE: Baseline is Mean (STDEV); CFBL is Mean (SE); P-values are nominal 2-sided;

  19. Slide 19: Phase 3 PROPEL Study Publication

    19 Phase 3 PROPEL Study Publication Clinically Meaningful Outcomes from Phase 3 PROPEL Study Provide the Basis for Global Regulatory Submissions of AT-GAA Peer-reviewed results from PROPEL suggest that treatment with AT-GAA provided clinically meaningful improvements over standard of care, including

  20. Slide 20: Long-Term Data from Phase 1/2 Clinical Study

    20 Long-Term Data from Phase 1/2 Clinical Study (ATB200-02) Persistent and Durable Improvements in Motor and Respiratory Function and Reductions in Biomarkers of Muscle Damage and Disease Substrate Observed in Patients out to 48 Months NOTE: * One patient in the ERT-naïve cohort experienced a large

  21. Slide 21: AT-GAA: Ongoing Evidence Generation

    21 AT-GAA: Ongoing Evidence Generation Indirect Treatment Comparison across Pompe ERT Studies Recently Presented at World Muscle Society 2022 Congress Highlights Potential Clinical Differentiation of AT-GAA 6MWD: Relative effect estimates with 95% credible intervals in base-case scenario -100-50-050

  22. Slide 22: Global Pompe Market

    22 Global Pompe Market Global Pompe Disease Market Growth Continues to be Driven by the Diagnosis of New Patients -Only One Approved Therapy on the Market up until 2021 Pompe Disease believed to be significantly underdiagnosed–Newborn screening studies suggests Pompe to be more prevalent than medica

  23. Slide 23: AT-GAA: Key Takeaways

    23 AT-GAA: Key Takeaways U.S. Regulatory status update: –PDUFA action date deferred due to Agency‘s inability to conduct manufacturing inspection in China1–At the Agency’s direction, the Company has scheduled a Type A meeting to develop plans and logistics for a pre-approval inspection European Regu

  24. Slide 24: AT-GAA Launch Preparations

    24 AT-GAA Launch Preparations Experienced and Passionate Rare Disease Medical and Commercial Organization Poised for SecondSuccessful Launch Key Strengths Commitment to patient accessClear focus on launchIdentification of key Pompe disease treatment centersDevelopment of educational materials Planni

  25. Slide 25: Financial & Operational Strategy

    25 Financial & Operational Strategy… maintaining a strong financial outlook

  26. Slide 26: Q3 2022 Revenue Performance

    26 Q3 2022 Revenue Performance Q3 2022 Reported Revenue Growth of +2.7% to $81.7M resulting from Strong Operational Growth of +13.6% at CER Offset by Negative FX impact of -10.9% Significant currency exposure as 63% of Galafold revenue generated outside the U.S. Applying average October 2022 exchang

  27. Slide 27: Financial Outlook and Path to Profitability

    Financial Outlook and Path to Profitability Clear Strategy to Build Our Business, Advance Our Portfolio, and Achieve Profitability 27 Sustain Galafold Revenue GrowthDeliver on Financial GoalsSecure Approvals of AT-GAA$241M YTD revenue, +16.2% YoY Operational Growth 2022 Galafold revenue growth guida

  28. Slide 28: True Measure of Success: Impacting the Lives of Patients

    28 True Measure of Success: Impacting the Lives of Patients Living with Rare Diseases YE17 2023+Thousands of Patients*>1,900+ Patients* YE21 >350 Patients* *Clinical & commercial, all figures approximate

  29. Slide 29: Thank You

    Amicus herapeutics Thank You

  30. Slide 30: Appendix

    Amicus herapeutics Appendix

  31. Slide 31: Environmental, Social, & Governance (ESG) Snapshot

    31 Environmental, Social, & Governance (ESG) Snapshot Board of Directors Eco-friendly decision-making has unearthed economic efficiencies while continuing to bolster our standing as a good corporate citizen.Committed to ongoing Board refreshment and diversity of background, gender, skills, and exper

  32. Slide 32: Reconciliation of Non-GAAP Financial Measures

    Appendix Total operating expenses - as reported GAAP Research and development: Share-based compensation Selling, general and administrative: Share-based compensation ‘Loss on impairment of assets Changes in fair value of contingent consideration payable Depreciation and amortization Total operating

Amicus Therapeutics — Investor Presentation (November 2022) on 6ix